5 listed sites: Taiwan (1); United States (4) - 30 Dec `25EI-001 antibody treatment for nonsegmental vitiligo

EI-001 antibody treatment for nonsegmental vitiligo

Official title: A Phase 2, Randomized, Double-Blind, Placebo-controlled Proof-of-Concept Study to Evaluate the Efficacy and Safety of EI-001 in Patients With Nonsegmental Vitiligo

Status: Recruiting now

Description:

Elixiron Immunotherapeutics (Hong Kong) Ltd. plans to enroll about 45 participants. EI-001 is an experimental antibody that blocks interferon-gamma, an inflammatory signal involved in melanocyte damage. Researchers hope it will protect pigment-producing cells and support repigmentation. Possible risks include infusion or allergic reactions, headache, and infections; its full safety profile is not yet known. People ages 18 to 65 may qualify. The study is recruiting at 6 listed sites in United States, and Taiwan.

Start date: December 30, 2025

Completion date: September 30, 2027

Organizer: Elixiron Immunotherapeutics (Hong Kong) Ltd.

Contact: Matthew Campos Site Coordinator

Tel.: 714-375-5970

Email: mcampos@marvelclinical.com

Link: https://clinicaltrials.gov/study/NCT07223229

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference EI-001 antibody treatment for nonsegmental vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions